“…Experimental studies have revealed that certain types of cancer cells are more susceptible to CAP treatment and oxidative damage compared to normal cells [ 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 ], although the reported selectivity depends on cell type and culture medium [ 24 ]. CAP exhibits therapeutic potential against various types of cancer [ 25 ], including hepatocellular carcinoma [ 26 ], lung carcinoma [ 27 ], breast cancer [ 28 ], melanoma [ 18 ], glioblastoma [ 29 ], pancreatic cancer [ 30 ], and head and neck cancer [ 31 ]. Intracellular RONS levels induced by CAP treatment in cancer therapies can cause irreversible damage to cellular components, particularly proteins, lipids, and DNA, ultimately leading to tumor cell death [ 32 , 33 , 34 ].…”